Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer.

doi:10.1200/JCO.2013.51.4737

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Apr 2014

Guarneri Valentina, Generali Daniele Giulio, Frassoldati Antonio, Artioli Fabrizio, Boni Corrado, Cavanna Luigi, Tagliafico Enrico, Maiorana Antonino, Bottini Alberto, Cagossi Katia, Bisagni Giancarlo, Piacentini Federico, Ficarra Guido, Bettelli Stefania, Roncaglia Enrica, Nuzzo Simona, Swaby Ramona, Ellis Catherine, Holford Clare, Conte Pierfranco

Abstract excerpt

PURPOSE: This is a randomized, double-blind, placebo-controlled study aimed to evaluate the clinical and biologic effects of letrozole plus lapatinib or placebo as neoadjuvant therapy in hormone receptor (HR) -positive/human epidermal growth factor receptor 2 (HER2) -negative operable breast cancer. METHODS: Ninety-two postmenopausal women with stage II to IIIA primary breast cancer were randomly assigned to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Double-Blind Method

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ki-67 Antigen

Share to Lapatinib

Share to Neoadjuvant Therapy

Share to Nitriles

Share to Postmenopause

Share to Receptors, Progesterone

Share to Triazoles

Source

Open in PubMed

Identifiers

PMID: 24590635
DOI: 10.1200/JCO.2013.51.4737

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer.PMID 24590635Read ↗

Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.Semantic proximity Read ↗

A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer.Semantic proximity Read ↗

Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).Semantic proximity Read ↗

Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer.Semantic proximity Read ↗

A Phase I/II Study of Preoperative Letrozole, Everolimus, and Carotuximab in Stage 2 and 3 Hormone Receptor-positive and Her2-negative Breast Cancer.Semantic proximity Read ↗

Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer.Semantic proximity Read ↗

PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib.Semantic proximity Read ↗

A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer.Semantic proximity Read ↗

Translating neoadjuvant therapy into survival benefits: one size does not fit all.Semantic proximity Read ↗

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.Semantic proximity Read ↗

Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone.Semantic proximity Read ↗

Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profilesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.